Table of Contents
TARGETED THERAPY FOR FLUOROQUINOLONES IN INFANTS AND CHILDREN
WHY FQ THERAPY FOR MENINGITIS
ANTIBIOTIC THERAPY IN EXPERIMENTAL MENINGITIS: RELEVANT PRINCIPLES
DETERMINING ANTIBIOTIC REGIMEN IN HUMANS FROM EXPERIMENTAL MENINGITIS MODEL
PPT Slide
TROVAFLOXACIN STUDY DEMOGRAPHICS*
CLINICAL AND MICROBIOLOGIC OUTCOMES OF EVALUABLE PATIENTS*
CLINICAL OUTCOME: ITT ANALYSIS
TROVAFLOXACIN STUDY: ADVERSE EVENTS (ITT)*
RESTRICTIONS ON PERFORMING STUDIES OF ANTIBIOTIC THERAPY FOR MENINGITIS
REQUISITES TO CONDUCTING INTERNATIONAL STUDIES
ANALYSIS OF EQUIVALENCE OR NON-INFERIORITY
EQUIVALENCE OF THERAPEUTIC AGENTS
SAMPLE SIZE ESTIMATIONS (using ? = .05 AND ß = .20)
EQUIVALENCE IN RANDOMIZED CONTROLLED TRIALS OF THERAPY FOR BACTERIAL MENINGITIS*
POTENTIAL PROBLEMS WITH ENROLLING MENINGITIS PATIENTS FROM DEVELOPING COUNTRIES
ROLE OF ANTIBIOTICS FOR MENINGITIS THERAPY
BACTERIOLOGIC SUCCESS OF TROVAFLOXACIN VS CEFTRIAXONE IN BACTERIAL MENINGITIS
DELAYED CSF STERILIZATION AND OUTCOME IN BACTERIAL MENINGITIS*
CRITICAL ENDPOINTS FOR ASSESSING EFFECTIVENESS OF ABX FOR MENINGITIS
|